13.12 USD
▼-0.10-0.76%
盘后 15.65 0.00%
2026-11-20
市值
$228.58M
市盈率
—
EPS
-7.93
股息率
—
52 周区间
12.58 – 39.60
成交量
19.32K
Beta
—
目标价
57.00
52W 低 12.5852W 高 39.60
价格走势
公司简介
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and ...